BEAM
HEALTHCAREBeam Therapeutics Inc
$32.34+3.44 (+11.90%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BEAM Today?
No stock-specific AI insight has been generated for BEAM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$15.35$36.44
$32.34
Fundamentals
Market Cap$3.2B
P/E Ratio—
EPS$-0.81
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding102.7M
BEAM News
21 articles- Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesYahoo Finance·May 7, 2026
- Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake DisclosureYahoo Finance·May 4, 2026
- Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In FocusYahoo Finance·May 3, 2026
- Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?Yahoo Finance·May 2, 2026
- Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have GrowthYahoo Finance·May 1, 2026
- Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”Yahoo Finance·Apr 30, 2026
- Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON StudyYahoo Finance·Apr 29, 2026
- 3 Biotech Stocks That Could Benefit from the Patent CliffMarketbeat·Apr 27, 2026
- Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed?Yahoo Finance·Apr 16, 2026
- Three Best Genomics Stocks for Your Portfolio in 2026Yahoo Finance·Apr 13, 2026
- Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution247 Wall St·Apr 12, 2026
- Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.The Motley Fool·Apr 11, 2026
- Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical ApplicationsGlobeNewswire Inc.·Apr 7, 2026
- Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 YearsYahoo Finance·Apr 2, 2026
- Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of MedicineYahoo Finance·Apr 1, 2026
- How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And FundingYahoo Finance·Mar 27, 2026
- BEAM Eyes Global Expansion of AATD Study After Strong Early DataYahoo Finance·Mar 26, 2026
- Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026Marketbeat·Mar 25, 2026
- Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentGlobeNewswire Inc.·Mar 25, 2026
- Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?Yahoo Finance·Mar 12, 2026
All 21 articles loaded
Price Data
Open$30.67
Previous Close$28.90
Day High$31.24
Day Low$28.50
52 Week High$36.44
52 Week Low$15.35
52-Week Range
$15.35$36.44
$32.34
Fundamentals
Market Cap$3.2B
P/E Ratio—
EPS$-0.81
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.6%
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding102.7M
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—